[Assessment of nonpenetrating deep sclerectomy with reticulated hyaluronic acid implant SKGEL and/or preoperative application of 5-luorouracil: results of 2 and a half years].
OBJECTIVE
To assess the effectiveness and the safety of deep sclerectomy (DS) with reticulated hyaluronic acid implant (SKGEL) and/or 5-Fluorouracile (5-FU).


METHODS
42 phakic eyes (42 patients) (mean age: 61.0 +/- 11.5 years) with medically uncontrolled open angle glaucoma and without history of previous filtering procedure were included in this non-randomized retrospective study. According to the peroperative protocol, the patients were categorized into 3 groups: DS + SKGEL (7 eyes), DS + 5-FU (50/mg/ml during 3 minutes) (13 eyes) and group C with SKGEL and 5-FU simultaneously (22 eyes).


RESULTS
The mean follow up was 30.6 +/- 9.2 months and was significantly shorter in group C. The 3 groups were comparable with respect to the age of the patients, the severity of glaucomatous defects, the distribution of the target IOP, the mean number and duration of preoperative medications as well as to the mean preoperative visual acuity and IOP. The mean IOP was significantly decreased from 27.3 +/- 3.2 mm Hg to 16.1 +/- 3.7 3.7 mm Hg (p < 0.0001) and was not significantly different between the 3 groups at 24 months follow up (p > 0.05). Mean visual acuity was not significantly altered in the 3 groups (p > 0.05). Complete (target IOP reached without medication or YAG laser goniopuncture) and qualified (target IOP reached with medication and/or YAG laser goniopuncture) final success rates were respectively 33.3% and 83.3%. The frequency of distribution of success was not significantly different between the 3 groups but the percentage of success was 100% in group A, 84.6% in group B and 77.2% in group C. Subconjunctival injections were needed in 33% in the first postoperative month. (group A: 28.5%; group B: 46.2%; group C: 27.2%) (X2 p > 0.05). Postoperative complications were relatively minor and were observed in 66% (P > 0.05 between the 3 groups). YAG laser goniopunctures were performed in 38% (group A: 16.6%; group B: 61.5%; group: 33.3%, X2 p > 0.05). Complete and qualified success probability were better in SKGEL group comparatively with the other 2 groups.


CONCLUSIONS
Considering its limitations and with a follow-up of 2 years and half, this study could confirm the safety and the efficacy of DS in return for which topical medication(s) and/or YAG laser gonioperforations were needed in a relatively high percentage of the cases. The benefits of the SKGEL implant on the quality of the IOP control appeared to be higher than 5-FU.
Detry-Morel
M
M
Cliniques Universitaires St Luc, UCL, Bruxelles. detry@ofta.ucl.ac.be
De Temmerman
S
S
D000328:Adult; D000368:Aged; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000628:therapy*; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D007429:Intraocular Pressure; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012599:Sclerostomy / Q000379:methods*; D016896:Treatment Outcome
D006820:Hyaluronic Acid; D005472:Fluorouracil